Full Text
EE141 Cost-Effectiveness of TP53 and IGHV Biomarker Testing Prior to First-Line Treatment With Novel Agents for Chronic Lymphocytic Leukemia

Abstract

Authors

M Vu K Degeling E Thompson P Blombery DA Westerman M IJzerman

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×